Madrigal Pharmaceuticals (MIL:1MDGL) Moat Score: 6/10 (As of Jul. 03, 2026)


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €460.60
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Moat Score?

Madrigal Pharmaceuticals MIL:1MDGL -2.48% 8 Moat Score is 6 as of Jul. 03, 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,400 Biotechnology companies, Madrigal Pharmaceuticals ranks better than 98.93% on this metric.

Madrigal Pharmaceuticals has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Madrigal Pharmaceuticals has Narrow Moat: Madrigal Pharmaceuticals Inc has a strong narrow moat due to its valuable intellectual property and consistent R&D capabilities. The company benefits from regulatory barriers but lacks strong brand strength and network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Madrigal Pharmaceuticals might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Madrigal Pharmaceuticals  (MIL:1MDGL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Madrigal Pharmaceuticals Moat Score Related Terms

MIL:1MDGL vs BMRN, AXSM, CYTK: Moat Score Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Moat Score falls into.


MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Madrigal Pharmaceuticals (MIL:1MDGL) has a Moat Score of 6 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #15 out of 1400 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Madrigal Pharmaceuticals' Moat Score too high?
Madrigal Pharmaceuticals' current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Madrigal Pharmaceuticals' value of 6 is 200% above this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #15 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Moat Score compare to BMRN and AXSM?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #15 out of 1400 companies for Moat Score. This places Madrigal Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Madrigal Pharmaceuticals' value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Moat Score of 6. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Moat Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€460.60
Price